Citius Pharmaceuticals, Inc.
NasdaqCM:CTXR Rapporto sulle azioni
Cap. di mercato: US$74.4m
Citius Pharmaceuticals Crescita futura
Future criteri di controllo 5/6 Si prevede che Citius Pharmaceuticals aumenterà gli utili e i ricavi rispettivamente del 49.9% e 44.8% all'anno, mentre si prevede che l'EPS crescerà del 50.1% all'anno.
Informazioni chiave
49.9%
Tasso di crescita degli utili
50.1%
Tasso di crescita dell'EPS
Pharmaceuticals crescita degli utili 23.8% Tasso di crescita dei ricavi 44.8% Rendimento futuro del capitale proprio n/a Copertura analitica Low
Ultimo aggiornamento 19 Aug 2024
Aggiornamenti recenti sulla crescita futura
Price target increased by 22% to US$4.67 Jul 16
Forecast breakeven date pushed back to 2026 Jun 03
Forecast breakeven date pushed back to 2026 Feb 23
Price target decreased by 21% to US$3.17 Aug 01
Consensus EPS estimates fall by 24% May 21
Forecast breakeven date pushed back to 2025 Apr 11
Mostra tutti gli aggiornamenti
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (Keytruda®) and Lymphir™ in Cancer Patients with Recurrent Solid Tumors Nov 12
Citius Pharmaceuticals, Inc. Provides Non-Compliance Update Sep 12
New minor risk - Market cap size Sep 04 Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $50 million. Aug 13
Citius Pharmaceuticals, Inc. Receives FDA Approval for LYMPHIR Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma Aug 08
Price target increased by 22% to US$4.67 Jul 16
Forecast breakeven date pushed back to 2026 Jun 03
Citius Pharmaceuticals, Inc. Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution May 22 Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $15.000002 million. May 01
Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma Apr 11
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully Apr 06
New minor risk - Share price stability Apr 01
The Nasdaq Stock Market LLC Grants Citius Pharmaceuticals' Request for an Extension through September 9, 2024 to Evidence Compliance with the Bid Price Rule Pursuant to Nasdaq Listing Rule 5550(a)(2) Mar 14
Forecast breakeven date pushed back to 2026 Feb 23
Citius Pharmaceuticals, Inc. Announces the Resubmission of the Biologics License Application to the U.S. Food and Drug Administration for Lymphir Feb 14
New minor risk - Market cap size Feb 01
Citius Pharmaceuticals, Inc., Annual General Meeting, Mar 12, 2024 Jan 24
Citius Pharmaceuticals, Inc. Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok Therapeutic to Salvage Catheters Jan 02
New major risk - Financial position Dec 31
New minor risk - Profitability Dec 29
We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate Dec 08
Citius Pharmaceuticals, Inc. Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor Nov 01
New minor risk - Share price stability Oct 25
Citius Pharmaceuticals, Inc. Announces Changes to its Audit Committee Sep 26
Citius Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Stock Market Sep 16
Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration Regarding the Planned Resubmission of the BLA for LYMPHIR Sep 09
Citius Pharmaceuticals, Inc. Reaches 92 Event Milestone in Mino-Lok Phase 3 Trial Aug 11
Price target decreased by 21% to US$3.17 Aug 01
Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely? Aug 01
Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma Jul 30
Citius Pharmaceuticals, Inc. Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids Jun 21
Consensus EPS estimates fall by 24% May 21
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth Apr 12
Forecast breakeven date pushed back to 2025 Apr 11
Price target increased by 25% to US$5.00 Mar 29
Forecast breakeven date pushed back to 2025 Feb 16
Citius Pharmaceuticals, Inc. Appoints Dennis M. McGrath to Board of Directors Feb 08
Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation Dec 25
Citius Pharmaceuticals, Inc., Annual General Meeting, Feb 07, 2023 Dec 23
Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma Dec 02
Price target decreased to US$3.60 Nov 16
Insufficient new directors Nov 16
Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma Sep 29
Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK Sep 28
Citius Pharmaceuticals GAAP EPS of -$0.06 Aug 11
Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely Aug 05
Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma Jul 13
Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK Jul 12
Citius Pharmaceuticals: Hoping For A Turnaround Strategy Jul 05
Price target increased to US$4.00 Apr 27
Insufficient new directors Apr 27
Citius Pharmaceuticals, Inc. Enrolls First Patient in Phase 2B Study of Halo-Lido for the Prescription Treatment of Hemorrhoids Apr 27 Citius Pharmaceuticals, Inc. Announces Executive Changes
Critical Care Biopharma - Citius Pharmaceuticals Apr 13
Forecast breakeven date pushed back to 2024 Apr 08
Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/Ontak (E7777) Apr 07
Citius: 2022 Is A Year Of Catalysts Mar 28
Citius Pharmaceuticals Announces FDA Acceptance of IND Application for its Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids Feb 16
Forecast breakeven date moved forward to 2023 Jan 21
Citius Pharmaceuticals, Inc. Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma Dec 07
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth Dec 04
Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization Sep 26
Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications Sep 08
Citius Pharmaceuticals, Inc. (NasdaqCM:CTXR) agreed to acquire Rights and Certain Related Assets of Dr. Reddy's Laboratories Limited (BSE:500124) for approximately $150 million. Sep 06
Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth Aug 28
Citius Pharmaceuticals, Inc. Announces Positive Recommendation by Independent Data Monitoring Committee to Continue the Mino-Lok® Phase 3 Trial as Planned Jul 03
Citius: Halt For Superiority On The Horizon Jun 15
Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial Jun 09
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth May 15
Citius Pharmaceuticals, Inc. Reports Strong Clinical Community Engagement During Mino-Lok Phase 3 Trial-Related Webinar Apr 30
Citius Pharmaceuticals shares rise in anticipation of Mino-Lok phase 3 results Apr 26
Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $76.500002 million. Feb 20
New 90-day high: US$1.69 Feb 17
Citius Pharmaceuticals to Present Update on Mino-Lok and Other Therapies At the Virtual Investor Conferences Small and Microcap Showcase on February 4 Feb 03
Citius Pharmaceuticals, Inc. announced that it has received $20.000012 million in funding Jan 28
Citius Pharmaceuticals, Inc. announced that it expects to receive $20.000012 million in funding Jan 26
New 90-day high: US$1.33 Jan 20
Citius Pharmaceuticals, Inc., Annual General Meeting, Feb 09, 2021 Dec 23
Is Citius Pharmaceuticals (NASDAQ:CTXR) In A Good Position To Deliver On Growth Plans? Dec 18
Citius Pharmaceuticals, Inc.'s Mino-Lok Trial Sites Resupplied with Registration Batch Product Oct 03
Citius Pharmaceuticals Reports Positive Results from Recent Data Monitoring Committee Meeting for Mino-Lok Phase 3 Trial Sep 30
New 90-day low - US$0.85 Sep 03
Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $8.363044 million. Aug 07
New 90-day high - US$1.48 Jul 18
Citius Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements Jul 17
Previsioni di crescita degli utili e dei ricavi NasdaqCM:CTXR - Stime future degli analisti e dati finanziari passati (USD Millions ) Data Ricavi Guadagni Flusso di cassa libero Liquidità dell'operazione Avg. Numero di analisti 9/30/2027 353 200 209 209 2 9/30/2026 238 128 160 160 2 9/30/2025 86 15 38 38 3 9/30/2024 N/A -37 -28 -31 3 6/30/2024 N/A -40 -29 -29 N/A 3/31/2024 N/A -37 -30 -30 N/A 12/31/2023 N/A -39 -30 -30 N/A 9/30/2023 N/A -34 -29 -29 N/A 6/30/2023 N/A -31 -29 -29 N/A 3/31/2023 N/A -31 -27 -27 N/A 12/31/2022 N/A -28 -29 -29 N/A 9/30/2022 N/A -34 -28 -28 N/A 6/30/2022 N/A -31 -68 -28 N/A 3/31/2022 N/A -29 -65 -25 N/A 12/31/2021 N/A -26 -59 -19 N/A 9/30/2021 N/A -25 -64 -24 N/A 6/30/2021 N/A -24 -22 -22 N/A 3/31/2021 N/A -21 -21 -21 N/A 12/31/2020 N/A -21 -21 -21 N/A 9/30/2020 N/A -18 -17 -17 N/A 6/30/2020 N/A -17 -16 -16 N/A 3/31/2020 N/A -17 -16 -16 N/A 12/31/2019 N/A -16 -15 -15 N/A 9/30/2019 N/A -16 -12 -12 N/A 6/30/2019 N/A -15 -12 -12 N/A 3/31/2019 N/A -12 -11 -11 N/A 12/31/2018 N/A -13 -11 -11 N/A 9/30/2018 N/A -13 -11 -11 N/A 6/30/2018 N/A -13 -12 -12 N/A 3/31/2018 N/A -13 N/A -12 N/A 12/31/2017 N/A -11 N/A -9 N/A 9/30/2017 N/A -10 N/A -8 N/A 6/30/2017 N/A -10 N/A -6 N/A 3/31/2017 N/A -11 N/A -6 N/A 12/31/2016 N/A -9 N/A -7 N/A 9/30/2016 N/A -8 N/A -6 N/A 6/30/2016 N/A -7 N/A -5 N/A 3/31/2016 N/A -4 N/A -3 N/A 12/31/2015 N/A -3 N/A -2 N/A 9/30/2015 N/A -3 N/A -2 N/A 6/30/2015 N/A -3 N/A -2 N/A 3/31/2015 N/A -2 N/A -1 N/A 12/31/2014 N/A -2 N/A -1 N/A 9/30/2014 N/A -1 N/A -1 N/A 6/30/2014 N/A -1 N/A -1 N/A 3/31/2014 N/A -1 N/A -1 N/A
Mostra di più
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che CTXR diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 2.6% ).
Guadagni vs Mercato: Si prevede che CTXR diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.
Guadagni ad alta crescita: Si prevede CTXR diventerà redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di CTXR ( 44.8% all'anno) crescerà più rapidamente del mercato US ( 8.9% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di CTXR ( 44.8% all'anno) crescerà più rapidamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Dati insufficienti per determinare se il Return on Equity di CTXR è previsto essere elevato tra 3 anni
Scoprire le aziende in crescita Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
